Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
The initial experience of safety and efficacy of argon plasma coagulation (APC) in the primary prevention of variceal bleeding.
Arab J Gastroenterol
September 2012
Tropical Medicine Department, Faculty of Medicine, Cairo University, Cairo, Egypt.
Background And Study Aims: The well-known complications of variceal bleeding together with the high mortality rate mandate effective prophylaxis. Because of the intolerance, failure of response and lack of compliance related to B blockers and because of the high incidence of variceal recurrence after endoscopic variceal ligation (EVL), other alternatives should be investigated. As APC provides coagulation at a shallow depth, it has been considered an ideal procedure to promote mucosal fibrosis for oesophageal varices.
View Article and Find Full Text PDFCirrhotic portal hypertension: current and future medical therapy for primary and secondary prevention of variceal bleeding.
Minerva Med
August 2006
Department of Hepatology, University Hospital Gasthuisberg, K.U. Leuven, B-3000 Leuven, Belgium.
Portal hypertension (PHT) is the most common complication of chronic liver disease and develops in the vast majority of patients with cirrhosis. It is characterized by an increase of the portal vein pressure, and leads to the development of gastroesophageal varices, ascites, renal dysfunction and hepatic encephalopathy. Over the years, it has become clear that a decrease in portal pressure is not only protective against the risk of variceal (re)bleeding but is also associated with a lower long-term risk of developing other complications and with an improved long-term survival.
View Article and Find Full Text PDF[Pathogenesis of portal hypertension].
Rev Invest Clin
March 2006
Residente de tercer año de Gastroenterología, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán.
It is now well established that portal hypertension is not a purely mechanical phenomenon. Primary hemodynamic alterations develop in the hepatic and systemic circulatory systems; these alterations in combination with mechanical factors contribute to the development of portal hypertension. In the hepatic circulation, these hemodynamic alterations are characterized by vasoconstriction and impaired hepatic vasodilatory responses, whereas in the systemic circulation, particularly in the splanchnic bed, vessels are hyperemic with increased flow.
View Article and Find Full Text PDFDrug treatment for portal hypertension.
Ann Hepatol
September 2004
Liver Transplantation and Hepatobiliary Medicine, Royal Free Hospital, London, England.
Pharmacological treatment of portal hypertension has played an increasing clinical role in the past 20 years. In the setting of acute variceal bleeding, drug therapy should be considered the initial treatment of choice and can be administered as soon as possible; even during the transfer of the patient to hospital. Several recent trials have reported similar efficacy to emergency sclerotherapy, therefore drug treatment should no longer be considered as a "stop gap" therapy until definitive endoscopic therapy is performed but continued for several days.
View Article and Find Full Text PDFPrevention of variceal rebleeding.
Lancet
March 2003
Hepatic Haemodynamic Laboratory, Liver Unit, Institut de Malalties Digestives, Hospital Clínic, IDIBAPS, University of Barcelona, 08036, Barcelona, Spain.
Context: Variceal bleeding is the most frequent severe complication of portal hypertension and a leading cause of death and liver transplantation in patients with cirrhosis. Patients surviving a variceal bleed are at high risk of rebleeding (over 60% at 1 year). Portacaval shunts and transjugular intrahepatic portasystemic shunts (TIPS) are effective for prevention of rebleeding but carry a high risk of hepatic encephalopathy.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!